AzTrials
AzTrials

Metabolic SyndromeMOINCT04314258

Effect of Moringa Oleifera Infusion on Health

A study testing Moringa oleifera tea in people with Metabolic Syndrome, run by University of Mauritius at 1 site in Mauritius.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study aims at investigating the effects of the consumption of Moringa oleifera Lam leaves on biomedical markers of health among healthy individuals who are hyperglycaemic with a fasting blood glucose equal or greater than 5.5mmol/L. The main objectives are as follows: 1. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Metabolic Syndrome
What is being tested?
Moringa oleifera tea
Could I receive a placebo?
No, everyone receives an active treatment
How many people
103 participants
Where
1 siteMauritius
Study dates
10 Feb 2020to 31 Aug 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy subjects with normal fasting plasma glucose levels
  • Individuals with pre-diabetes condition newly diagnosed
  • Individuals with dyslipidemia
  • Type 2 Diabetes patients taking oral allopathic hypoglycemic agents

Who cannot join

  • Pregnant women
  • Smokers
  • People with alcohol intake >2 standard drinks per day (in line with Bahorun et al. 2012)
  • Patients with any complications of diabetes mellitus
  • Patients on insulin therapy (in line with Leone et al. 2018)
  • Patients with gastro-intestinal, hepatic, cardiovascular, renal or endocrine disorder (other than diabetes mellitus) which can interfere with the absorption, metabolism and excretion of Moringa leaves (in line with Bahorun et al. 2012)
Show all 10Show fewer
  • Patients on medication for diseases other than diabetes
  • Persons taking botanical extracts
  • People currently on a diet (in line with Ahmad et al. 2018)
  • People having food allergies.

Trial locations and contacts

1 site in 1 country.

Mauritius1 site
  • University of Mauritius

    Moka, Please Select, 80811

Other trials in Mauritius

About this study

Official title: Randomized Clinical Study Investigating the Effect of Moringa Oleifera Infusion on Bioclinical Parameters of Health

The study aims at investigating the effects of the consumption of Moringa oleifera Lam leaves on biomedical markers of health among healthy individuals who are hyperglycaemic with a fasting blood glucose equal or greater than 5.5mmol/L.

The main objectives are as follows:

Read more
  1. To determine the effect of consuming 4 grams of Moringa oleifera Lam leaves infused in 200 ml of hot water twice daily on blood glucose level [BSc (Hons) Medical Science Student].
  2. To assess the effect of consuming 4 grams of Moringa oleifera Lam leaves infused in 200 ml of hot water twice daily on plasma lipids level [Master of Public Health Students].
  3. To compare the effect of the Moringa tea consumption on lipid profiles of both healthy and hyperglycemic participants [Master of Public Health Students].
  4. To evaluate the effects of Moringa oleifera Lam leaves on blood anti-oxidant status [BSc (Hons) Nutritional Sciences Student].

The research work will consist of (1) Experimental intervention: The experimental group will drink Moringa tea; (2) Survey questionnaire, (3) Anthropometric measurements, (4) Blood pressure determination and (5) Blood collections at 15-day intervals during 9 weeks. The blood tests to be performed are as follows: Glucose, HbA1C, Uric acid, C-Protein reactive, Lipid Profile (Total Cholesterol, HDL Cholesterol, Triglycerides), and blood antioxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity).

Read the detailed description

Study population

120 participants to include 60 healthy individuals and 60 individuals who are hyperglycaemic with a fasting blood glucose equal or greater than 5.5mmol/L will be recruited by means of flyers, posters and mass email by the help of Staff Club of the UoM.

Experimental design

This research work will to be undertaken under the responsibility and coordination of the Applicant who is the Principal Investigator working with two Academic Supervisors for the supervision of the four student projects.

This randomized clinical study will consist of two parallel groups with a crossover design.

There will be two arms as follows for each group:

  1. Intervention group [drinking Moringa tea] and
  2. Control group [drinking plain water].

Computer-generated random numbers will be used for simple randomization of subjects to either the experimental or control (equal amount of water) groups. Half of the participants will be assigned to the experimental group and the other control (water) for the first 4 weeks during Phase 1.

The experimental group will be provided with Moringa tea bags and instructed to consume twice daily 2 tea bags (4 tea bags equivalent to 8 grams) of Moringa tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.

With the cross over design, there will be two phases for both healthy and hyperglycaemic groups with an interchange of the groups during Phase 1 and 2 as follows:

Four-week Phase 1 - Group A drinking Moringa tea v/s Group B drinking plain water One-week washout Four-week Phase 2 - Group A drinking plain water v/s Group B drinking Moringa tea

The duration of the clinical study will normally be nine weeks with possible extension of four weeks.

Outcome Measurements Baseline data collection Measurements of body weight and blood pressure will be performed. Anthropometric measurements will be taken for each subject: Weight will be measured using an electronic weighing machine, height will be measured using a stadiometer, waist circumference will be measured using a non-stretchable measuring tape. Blood pressure will be measured using a sphygmomanometer.

Blood samples will be drawn by Specialized Nursing Officers from right or left ante-cubital vein of participant after a 12-h overnight fast. Blood tests which will be performed are as follows: Glucose, Lipid profile [Triglycerides, Total Cholesterol and HDL Cholesterol levels (LDL Cholesterol being calculated)], Uric Acid, HbA1C, C-Reactive Protein (hs-CRP) and Blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity).

Fortnight monitoring sessions All participants of the two groups will be monitored on a fortnight basis for body weight, height, waist circumference, blood pressure and specified blood tests. Food intake and physical exercise questionnaires will be collected from participants to determine confounding factors.

[The individual quantity of physical activity, in metabolic equivalent-minutes per week (MET-min/week), will be determined by using validated physical activity questionnaire].

Outcome Measurements Baseline data collection Measurements of body weight and blood pressure will be performed. Anthropometric measurements will be taken for each subject: Weight will be measured using an electronic weighing machine, height will be measured using a stadiometer, waist circumference will be measured using a non-stretchable measuring tape. Blood pressure will be measured using a sphygmomanometer.

Blood samples will be drawn by Specialized Nursing Officers from right or left ante-cubital vein of participant after a 12-h overnight fast. Blood tests which will be performed are as follows: Glucose, Lipid profile [Triglycerides, Total Cholesterol and HDL Cholesterol levels (LDL Cholesterol being calculated)], Uric Acid, HbA1C, C-Reactive Protein (hs-CRP) and Blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity).

Fortnight monitoring sessions All participants of the two groups will be monitored on a fortnight basis for body weight, height, waist circumference, blood pressure and specified blood tests. Food intake and physical exercise questionnaires will be collected from participants to determine confounding factors.

[The individual quantity of physical activity, in metabolic equivalent-minutes per week (MET-min/week), will be determined by using validated physical activity questionnaire].

Being tested
Moringa oleifera tea
Medical subject headings
Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Moringa oleifera teaDietary supplement

    4 grams of Moringa oleifera tea twice daily

Study groups in NCT04314258
Study groupRoleWhat they receive
Drinking Moringa oleifera teaExperimentalThe experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
Receives: Dietary Supplement: Moringa oleifera tea
Drinking plain waterNo interventionThe control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in blood glucose level

    Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)

    Measured: Eight weeks

  2. Change in Low-density Lipoprotein (LDL) Cholesterol level

    Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)

    Measured: Eight weeks

  3. Change in Triglyceride level

    Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)

    Measured: Eight weeks

Secondary outcomes (1)
  1. Change in levels of blood anti-oxidants

    Levels of blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity) will be monitored every fortnight during the 8-week clinical trial. C-Reactive Protein will also be measured.

    Measured: Eight weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2020
  2. Study start10 Feb 2020
  3. Primary completion30 Apr 2020 (estimated)
  4. Study completion31 Aug 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Model description
This randomized clinical study will consist of two parallel groups with a crossover design. There will be two arms as follows: 1. Intervention group \[Drinking Moringa tea\] 2. Control group \[Drinking plain water\]. Computer-generated random numbers will be used for simple randomization of subjects to either the experimental or control group. With the cross over design, there will be two phases with an interchange of the groups during Phase 1 and 2 as follows: Four-week Phase 1 - Group A drinking Moringa tea v/s Group B drinking plain water One-week washout Four-week Phase 2 - Group A drinking plain water v/s Group B drinking Moringa tea
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
103 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04314258
Sponsor's protocol ID
UOM002
Acronym
MOI
Status last verified
Mar 2020
First submitted
18 Feb 2020
Last updated
19 Mar 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Publications

  • Bahorun T, Luximon-Ramma A, Neergheen-Bhujun VS, Gunness TK, Googoolye K, Auger C, Crozier A, Aruoma OI. The effect of black tea on risk factors of cardiovascular disease in a normal population. Prev Med. 2012 May;54 Suppl:S98-102. doi: 10.1016/j.ypmed.2011.12.009. Epub 2011 Dec 16.

    PubMed 22198621
  • Leone A, Bertoli S, Di Lello S, Bassoli A, Ravasenghi S, Borgonovo G, Forlani F, Battezzati A. Effect of Moringa oleifera Leaf Powder on Postprandial Blood Glucose Response: In Vivo Study on Saharawi People Living in Refugee Camps. Nutrients. 2018 Oct 12;10(10):1494. doi: 10.3390/nu10101494.

    PubMed 30322091
  • Ahmad J, Khan I, Johnson SK, Alam I, Din ZU. Effect of Incorporating Stevia and Moringa in Cookies on Postprandial Glycemia, Appetite, Palatability, and Gastrointestinal Well-Being. J Am Coll Nutr. 2018 Feb;37(2):133-139. doi: 10.1080/07315724.2017.1372821. Epub 2017 Dec 22.

    PubMed 29272206
  • Kumari, D. J. (2010) 'Hypoglycaemic Effect of Moringa Oleifera and Azadirachta Indica in Type 2 Diabetes Mellitus', The Bioscan, 5(2), p. 4.

Questions about this trial

What is this clinical trial studying?

A study testing Moringa oleifera tea in people with Metabolic Syndrome, run by University of Mauritius at 1 site in Mauritius.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mauritius. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in blood glucose level (time frame: Eight weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04314258, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in